Radiopharm Theranostics Limited American Depositary Shares (RADX) - Net Assets
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has net assets worth $52.00 Million USD as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($92.45 Million) and total liabilities ($40.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Radiopharm Theranostics Limited American (RADX) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.00 Million |
| % of Total Assets | 56.25% |
| Annual Growth Rate | -12.02% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 42.98 |
Radiopharm Theranostics Limited American Depositary Shares - Net Assets Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's net assets have evolved over time, based on quarterly financial data. See RADX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
The table below shows the annual net assets of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025. For live valuation and market cap data, see Radiopharm Theranostics Limited American (RADX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $42.87 Million | +56.73% |
| 2024-06-30 | $27.35 Million | -39.99% |
| 2023-06-30 | $45.58 Million | -27.61% |
| 2022-06-30 | $62.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Radiopharm Theranostics Limited American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11490878300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $176.56 Million | 394.17% |
| Other Comprehensive Income | $13.12 Million | 29.28% |
| Other Components | $849.54K | 1.90% |
| Total Equity | $44.79 Million | 100.00% |
Radiopharm Theranostics Limited American Depositary Shares Competitors by Market Cap
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Big Digital Energy, Inc.
NASDAQ:BGDE
|
$34.07 Million |
|
Aberdeen Global IF Inc
NYSE MKT:FCO
|
$34.10 Million |
|
Accentis
BR:ACCB
|
$34.10 Million |
|
Big Camera Corporation Public Company Limited
BK:BIG
|
$34.10 Million |
|
Drone Volt SA
PA:ALDRV
|
$34.02 Million |
|
Zepp Health Corp
NYSE:ZEPP
|
$34.02 Million |
|
NUREXONE BIOLOGIC INC.
F:J90
|
$34.01 Million |
|
Vardhman Polytex Limited
NSE:VARDMNPOLY
|
$33.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Radiopharm Theranostics Limited American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,122,562 to 44,792,004, a change of 16,669,442 (59.3%).
- Net loss of 38,342,457 reduced equity.
- New share issuances of 53,977,902 increased equity.
- Other comprehensive income decreased equity by 24,813,153.
- Other factors increased equity by 25,847,150.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.34 Million | -85.6% |
| Share Issuances | $53.98 Million | +120.51% |
| Other Comprehensive Income | $-24.81 Million | -55.4% |
| Other Changes | $25.85 Million | +57.7% |
| Total Change | $- | 59.27% |
Book Value vs Market Value Analysis
This analysis compares Radiopharm Theranostics Limited American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.69x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.07x to 0.69x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | $61.76 | $4.45 | x |
| 2023-06-30 | $43.54 | $4.45 | x |
| 2024-06-30 | $21.83 | $4.45 | x |
| 2025-06-30 | $6.46 | $4.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Radiopharm Theranostics Limited American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -85.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1055.27%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.93x
- Recent ROE (-85.60%) is above the historical average (-95.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -48.19% | -343550.89% | 0.00x | 1.32x | $-36.64 Million |
| 2023 | -77.98% | -11838.59% | 0.00x | 1.69x | $-39.05 Million |
| 2024 | -170.50% | -16024.28% | 0.00x | 2.56x | $-50.76 Million |
| 2025 | -85.60% | -1055.27% | 0.04x | 1.93x | $-42.82 Million |
Industry Comparison
This section compares Radiopharm Theranostics Limited American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Radiopharm Theranostics Limited American Depositary Shares (RADX) | $52.00 Million | -48.19% | 0.78x | $34.06 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more